KURA Stock Up 35% after 5-Day Win Streak
Kura Oncology (KURA) stock hit day 5 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 35% return. The company has gained about $225 Mil in value over the last 5 days, with its current market capitalization at about $643 Mil. The stock remains 14.1% below its value at the end of 2024. This compares with year-to-date returns of 9.6% for the S&P 500.
KURA develops small molecule therapies targeting cancer, with lead candidates including ziftomenib and tipifarnib for treating solid tumors and blood-related cancers. After this rally, is KURA still a buy – or is it time to lock in gains? Deep dive with Buy or Sell KURA.
Comparing KURA Stock Returns With The S&P 500
The following table summarizes the return for KURA stock vs. the S&P 500 index over different periods, including the current streak:
- The Smart Way to Own ANET: Collect 10% Before You Even Buy
- Triggers That Could Ignite the Next Rally In Meta Platforms Stock
- Can Coca-Cola Stock Withstand These Pressures?
- Fiserv Stock: Strong Cash Flow Poised for a Re-Rating?
- Comcast Stock Pullback: A Chance to Ride the Uptrend
- Has Accenture Stock Quietly Become a Value Opportunity?
| Return Period | KURA | S&P 500 |
|---|---|---|
| 1D | 1.9% | -0.0% |
| 5D (Current Streak) | 35.0% | 1.2% |
| 1M (21D) | 17.6% | 2.4% |
| 3M (63D) | 24.3% | 8.2% |
| YTD 2025 | -14.1% | 9.6% |
| 2024 | -39.4% | 23.3% |
| 2023 | 15.9% | 24.2% |
| 2022 | -11.4% | -19.4% |
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 20 S&P constituents with 3 days or more of consecutive gains and 103 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 6 | 95 |
| 4D | 3 | 6 |
| 5D | 8 | 1 |
| 6D | 1 | 0 |
| 7D or more | 2 | 1 |
| Total >=3 D | 20 | 103 |
Key Financials for Kura Oncology (KURA)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $0 | $53.9 Mil |
| Operating Income | $-165.8 Mil | $-193.2 Mil |
| Net Income | $-152.6 Mil | $-174.0 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ1 | 2025 FQ2 |
|---|---|---|
| Revenues | $14.1 Mil | $15.3 Mil |
| Operating Income | $-64.7 Mil | $-72.7 Mil |
| Net Income | $-57.4 Mil | $-66.1 Mil |
While KURA stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.